Molecular pathology of urinary bladder cancer

George J. Netto, Liang Cheng

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The staggering advances in genetics and genomics achieved following the completion of the human genome project have deeply impacted clinical management and diagnostics in solid tumor oncology. Molecular diagnostics is now an integral part of routine clinical management in lung, colon, and breast cancer patients. In sharp contrast, molecular biomarkers have been largely excluded from current management algorithms of urologic malignancies. The need for new treatment alternatives to improve upon the so far modest outcome in muscle invasive bladder cancer patients is evident. Well-validated prognostic molecular biomarkers that can help clinicians identify patients in need of early aggressive management are lacking. Identifying robust predictive biomarkers that will stratify response to emerging targeted therapeutics is another crucially needed development. The following is an overview of the molecular pathways involved in bladder cancer oncogenesis with a focus on promising candidate biomarkers that may soon make their transition to the realm of clinical management of urothelial carcinoma.

Original languageEnglish (US)
Title of host publicationMolecular Surgical Pathology
PublisherSpringer New York
Pages229-253
Number of pages25
Volume9781461449003
ISBN (Print)9781461449003, 1461448999, 9781461448990
DOIs
StatePublished - May 1 2013

Fingerprint

Molecular Pathology
Urinary Bladder Neoplasms
Biomarkers
Human Genome Project
Genomics
Colonic Neoplasms
Lung Neoplasms
Neoplasms
Carcinogenesis
Breast Neoplasms
Carcinoma
Muscles
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Netto, G. J., & Cheng, L. (2013). Molecular pathology of urinary bladder cancer. In Molecular Surgical Pathology (Vol. 9781461449003, pp. 229-253). Springer New York. https://doi.org/10.1007/978-1-4614-4900-3_11

Molecular pathology of urinary bladder cancer. / Netto, George J.; Cheng, Liang.

Molecular Surgical Pathology. Vol. 9781461449003 Springer New York, 2013. p. 229-253.

Research output: Chapter in Book/Report/Conference proceedingChapter

Netto, GJ & Cheng, L 2013, Molecular pathology of urinary bladder cancer. in Molecular Surgical Pathology. vol. 9781461449003, Springer New York, pp. 229-253. https://doi.org/10.1007/978-1-4614-4900-3_11
Netto GJ, Cheng L. Molecular pathology of urinary bladder cancer. In Molecular Surgical Pathology. Vol. 9781461449003. Springer New York. 2013. p. 229-253 https://doi.org/10.1007/978-1-4614-4900-3_11
Netto, George J. ; Cheng, Liang. / Molecular pathology of urinary bladder cancer. Molecular Surgical Pathology. Vol. 9781461449003 Springer New York, 2013. pp. 229-253
@inbook{598dd7555c7641e38510be6396f74458,
title = "Molecular pathology of urinary bladder cancer",
abstract = "The staggering advances in genetics and genomics achieved following the completion of the human genome project have deeply impacted clinical management and diagnostics in solid tumor oncology. Molecular diagnostics is now an integral part of routine clinical management in lung, colon, and breast cancer patients. In sharp contrast, molecular biomarkers have been largely excluded from current management algorithms of urologic malignancies. The need for new treatment alternatives to improve upon the so far modest outcome in muscle invasive bladder cancer patients is evident. Well-validated prognostic molecular biomarkers that can help clinicians identify patients in need of early aggressive management are lacking. Identifying robust predictive biomarkers that will stratify response to emerging targeted therapeutics is another crucially needed development. The following is an overview of the molecular pathways involved in bladder cancer oncogenesis with a focus on promising candidate biomarkers that may soon make their transition to the realm of clinical management of urothelial carcinoma.",
author = "Netto, {George J.} and Liang Cheng",
year = "2013",
month = "5",
day = "1",
doi = "10.1007/978-1-4614-4900-3_11",
language = "English (US)",
isbn = "9781461449003",
volume = "9781461449003",
pages = "229--253",
booktitle = "Molecular Surgical Pathology",
publisher = "Springer New York",

}

TY - CHAP

T1 - Molecular pathology of urinary bladder cancer

AU - Netto, George J.

AU - Cheng, Liang

PY - 2013/5/1

Y1 - 2013/5/1

N2 - The staggering advances in genetics and genomics achieved following the completion of the human genome project have deeply impacted clinical management and diagnostics in solid tumor oncology. Molecular diagnostics is now an integral part of routine clinical management in lung, colon, and breast cancer patients. In sharp contrast, molecular biomarkers have been largely excluded from current management algorithms of urologic malignancies. The need for new treatment alternatives to improve upon the so far modest outcome in muscle invasive bladder cancer patients is evident. Well-validated prognostic molecular biomarkers that can help clinicians identify patients in need of early aggressive management are lacking. Identifying robust predictive biomarkers that will stratify response to emerging targeted therapeutics is another crucially needed development. The following is an overview of the molecular pathways involved in bladder cancer oncogenesis with a focus on promising candidate biomarkers that may soon make their transition to the realm of clinical management of urothelial carcinoma.

AB - The staggering advances in genetics and genomics achieved following the completion of the human genome project have deeply impacted clinical management and diagnostics in solid tumor oncology. Molecular diagnostics is now an integral part of routine clinical management in lung, colon, and breast cancer patients. In sharp contrast, molecular biomarkers have been largely excluded from current management algorithms of urologic malignancies. The need for new treatment alternatives to improve upon the so far modest outcome in muscle invasive bladder cancer patients is evident. Well-validated prognostic molecular biomarkers that can help clinicians identify patients in need of early aggressive management are lacking. Identifying robust predictive biomarkers that will stratify response to emerging targeted therapeutics is another crucially needed development. The following is an overview of the molecular pathways involved in bladder cancer oncogenesis with a focus on promising candidate biomarkers that may soon make their transition to the realm of clinical management of urothelial carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=84949175593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949175593&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-4900-3_11

DO - 10.1007/978-1-4614-4900-3_11

M3 - Chapter

AN - SCOPUS:84949175593

SN - 9781461449003

SN - 1461448999

SN - 9781461448990

VL - 9781461449003

SP - 229

EP - 253

BT - Molecular Surgical Pathology

PB - Springer New York

ER -